DK0407148T3 - Angiografisk hjælpestof - Google Patents

Angiografisk hjælpestof

Info

Publication number
DK0407148T3
DK0407148T3 DK90307268.4T DK90307268T DK0407148T3 DK 0407148 T3 DK0407148 T3 DK 0407148T3 DK 90307268 T DK90307268 T DK 90307268T DK 0407148 T3 DK0407148 T3 DK 0407148T3
Authority
DK
Denmark
Prior art keywords
angiographic
auxiliary
angiographic auxiliary
Prior art date
Application number
DK90307268.4T
Other languages
Danish (da)
English (en)
Inventor
Yasuyuki Gotou
Original Assignee
Taisho Pharmaceutical Co Ltd
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd, Green Cross Corp filed Critical Taisho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK0407148T3 publication Critical patent/DK0407148T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK90307268.4T 1989-07-05 1990-07-03 Angiografisk hjælpestof DK0407148T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1173709A JPH0669966B2 (ja) 1989-07-05 1989-07-05 血管造影補助剤

Publications (1)

Publication Number Publication Date
DK0407148T3 true DK0407148T3 (da) 1995-09-18

Family

ID=15965683

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90307268.4T DK0407148T3 (da) 1989-07-05 1990-07-03 Angiografisk hjælpestof

Country Status (8)

Country Link
US (1) US5445812A (ja)
EP (1) EP0407148B1 (ja)
JP (1) JPH0669966B2 (ja)
KR (1) KR0160127B1 (ja)
CA (1) CA2020368C (ja)
DE (1) DE69021289T2 (ja)
DK (1) DK0407148T3 (ja)
ES (1) ES2076320T3 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4135193C1 (ja) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
US5807895A (en) * 1994-11-29 1998-09-15 Schwarz Pharma, Inc. Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents
WO1996016661A2 (en) * 1994-11-29 1996-06-06 Schwarz Pharma, Inc. Use of prostaglandin e1, e2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents
DE4446694A1 (de) * 1994-12-09 1996-06-13 Schering Ag Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6281175B1 (en) 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
US6054421A (en) * 1997-09-23 2000-04-25 Scimed Life Systems, Inc. Medical emulsion lubricant
US6246897B1 (en) 1998-12-11 2001-06-12 General Electric Company Method and system for acquistion of preferential arterial and venous images for MR angiography
US6192264B1 (en) 1998-12-28 2001-02-20 General Electric Company Method and system for MRI venography including arterial and venous discrimination
US20080132797A1 (en) * 2002-12-10 2008-06-05 Knut Brabrand Monitoring infusion of a substance
AT518009A1 (de) * 2015-07-27 2017-06-15 Gebro Holding Gmbh Konzentrat enthaltend Alprostadil

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58222014A (ja) * 1982-06-18 1983-12-23 Taisho Pharmaceut Co Ltd プロスタグランジンｅ↓１脂肪乳剤
JPS59206349A (ja) * 1983-05-10 1984-11-22 Green Cross Corp:The プロスタグランジンｅ↓１誘導体
JPS59216820A (ja) * 1983-05-20 1984-12-06 Taisho Pharmaceut Co Ltd プロスタグランジン脂肪乳剤
JPH0818989B2 (ja) * 1984-01-12 1996-02-28 株式会社ミドリ十字 脂肪乳剤中のプロスタグランジンの安定化方法
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
JPS61289034A (ja) * 1985-06-17 1986-12-19 Teijin Ltd イソカルバサイクリン類脂肪乳剤
US4820732A (en) * 1985-10-04 1989-04-11 The Upjohn Company Method and compositions for reducing dysfunction in angioplasty procedures
US4955878A (en) * 1986-04-04 1990-09-11 Biotechnology, Inc. Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures
US5120527A (en) * 1989-10-19 1992-06-09 King Chuen Peter Li Paramagnetic oil emulsions as mri contrast agents
US5064636A (en) * 1989-10-19 1991-11-12 Li King C P Paramagnetic oil emulsions as enteric MRI contrast agents

Also Published As

Publication number Publication date
EP0407148A2 (en) 1991-01-09
KR0160127B1 (ko) 1998-12-01
DE69021289D1 (de) 1995-09-07
EP0407148A3 (en) 1992-01-08
KR910002470A (ko) 1991-02-25
CA2020368A1 (en) 1991-01-06
JPH0466540A (ja) 1992-03-02
US5445812A (en) 1995-08-29
DE69021289T2 (de) 1996-03-21
JPH0669966B2 (ja) 1994-09-07
EP0407148B1 (en) 1995-08-02
CA2020368C (en) 2001-09-11
ES2076320T3 (es) 1995-11-01

Similar Documents

Publication Publication Date Title
BR9002634A (pt) Poli-alfa-olefina
FI102501B1 (fi) Toimintoyksikkö
DE69033924D1 (de) Spiralabtastrechnertomographie
DK0407148T3 (da) Angiografisk hjælpestof
BR9000014A (pt) Classificaodr
NO922024L (no) Benzoksazinfarvestoffer
TR24963A (tr) Kendiliginden acilabilir semsiye
DD294367A5 (de) Farbbildroehre
BR9001818A (pt) Girotrom quase-otico
ATA149789A (de) Schienenrad
BR9006503A (pt) Copolimero agrilamidios
DD284561A5 (de) Chiptraeger
IT8943535A0 (it) Il cubotto
SE8903678D0 (sv) Le sans-gene
KR900015195U (ko) 해태 초제기
KR910007175U (ko) 캔
BR6902267U (pt) Grosalixa
BR6900207U (pt) Presilha-abracadeira
BR6901774U (pt) Negatoscopio unimaden
BR6901431U (pt) Bate-pula
BR6901354U (pt) Mosquetao
BR6900847U (pt) Tele-alarme
BR6900796U (pt) Eletro-lamina
BR6900735U (pt) Rotacesta
BR6901807U (pt) Fulao